Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium feredetate + ascorbic acid is a fixed-dose combination iron supplement used for the treatment and prevention of iron deficiency anemia. Sodium feredetate (sodium iron EDTA) is a stable chelated form of iron(III) that protects the iron from precipitating or binding to dietary inhibitors such as phytates and polyphenols in the gastrointestinal tract. This chelation enhances iron bioavailability, particularly in diets high in plant-based inhibitors, and is associated with a lower incidence of gastrointestinal side effects like constipation and nausea compared to traditional ferrous salts. Ascorbic acid (Vitamin C) is included to further enhance iron absorption by acting as a reducing agent, maintaining iron in its more soluble ferrous (Fe2+) state and facilitating its uptake via the divalent metal transporter 1 (DMT1) in the duodenal mucosa.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium feredetate + ascorbic acid.